As part of MLBT’s portfolio of investments we are proud to work with Heparin Therapeutics and have a recently published paper in a Lancet Group journal showing that inhaled, nebulised UFH is safe and significantly reduces intubation and mortality rates in ca. 500 hospitalised, non-intubated COVID-19 patients.